This One Data Readout Could Make Or Break Sellas Life Sciences Group

SELLAS Life Sciences Group is a high-conviction buy ahead of the pivotal Phase 3 REGAL trial readout for GPS in AML. The unusually long REGAL trial timeline suggests GPS may be delivering a meaningful survival benefit in a high-unmet-need AML population. SLS is well-funded into 2027, with $138.3 million in cash and targeted spending aligned to upcoming binary catalysts.

Seeking Alpha • Aug 13, 2026

SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

- Final Analysis of Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia to be Conducted Following the 80 th Event - - 28 Patients Enrolled in Phase 2 Trial of SLS009 in Newly Diagnosed First-Line AML; Topline Data Expected in Q4 2026 -  - Strong Preclinical Indications of Efficacy of SLS009 in Advanced Pancreatic Cancer Resistant to RAS inhibitors, Clinical Development Preparations Ongoing - - $138.3 Million in Cash and Cash Equivalents as of June 30, 2026 - NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. “The second quarter was an important period of execution for SELLAS as we continued to advance both of our lead clinical programs, GPS and SLS009,” said Angelos Stergiou, MD, ScD h.c.

GlobeNewsWire • Aug 11, 2026

Stock Picks From Seeking Alpha's July 2026 New Analysts

Seeking Alpha welcomed 33 new analysts in July 2026. This article showcases their top picks and investment strategies. Highlighted companies include SELLAS Life Sciences, Chevron, B2Gold, Amazon, and QXO, each with detailed investment theses. Analysts emphasize asymmetric opportunities, event-driven catalysts, balance sheet strength, market structure, and sector-specific growth or risk factors.

Seeking Alpha • Aug 6, 2026

SELLAS Life Sciences: The Ownership Structure Has Changed Before The Defining Catalyst

SELLAS Life Sciences enters its pivotal REGAL readout with a transformed shareholder base, stronger balance sheet, and a new supply structure. Institutional ownership doubled to 36.34%, with average allocation rising, reflecting both new and existing holders increasing stakes ahead of the binary event. Passive and index-linked funds now dominate SLS's register, while multi-strategy and quant funds have exited, reducing volatility-driven trading around the catalyst.

Seeking Alpha • Aug 2, 2026

SELLAS Life Sciences: Strong Buy-Imminent Catalyst, Dual-Platform Pipeline, And A Market That Hasn't Caught Up

SELLAS Life Sciences is at the center of a debate over its event-driven Phase 3 REGAL trial for GPS in AML CR2 patients. The extended REGAL timeline should not be interpreted as evidence of failure or success, given its event-driven design and recent protocol amendments. FDA-approved unlimited dosing and continued management confidence add nuance, but only final data will determine REGAL's outcome.

Seeking Alpha • Jul 14, 2026

SELLAS Life Sciences Shares Slip Wednesday as Price Tests $16 Resistance Wall

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Wednesday as investors take profits following the stock's strong longer-term uptrend, with broader risk appetite also softer across equities.

Benzinga • Jul 8, 2026

SELLAS Life Sciences Shares Fall Tuesday: What's Driving The Move?

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are trading lower Tuesday as traders digest the recent breakout run and early profit-taking shows up even with momentum still elevated from the company's latest corporate update.

Benzinga • Jun 30, 2026

Sellas Life Sciences: The AML Platform Is More Interesting Than The Binary Event

SELLAS Life Sciences is advancing a dual-path AML franchise with GPS nearing pivotal Phase 3 REGAL readout and SLS009 progressing in high-risk AML settings. SLS has strengthened its cash position to $135.8 million, providing a multi-year runway and flexibility ahead of critical data and potential commercialization. The REGAL trial's delayed event count sustains optimism for GPS efficacy in CR2 AML, with topline results imminent and BLA preparation underway.

Seeking Alpha • Jun 27, 2026

What's driving SLS stock higher today and what comes next?

Sellas Life Sciences (SLS) shares are extending gains on Jun. 26 following a key regulatory filing that disclosed a series of comprehensive corporate amendments regarding executive compensation and protection. Specifically, the board restructured change-of-control and severance agreements for CEO Angelos Stergiou, CFO John Burns, and CDO Dragan Cicic.

Invezz • Jun 26, 2026

SELLAS Stock Hits New Highs: What's Happening Today?

SELLAS Life Sciences Group Inc (NASDAQ:SLS) shares are pushing higher Friday morning, adding to Thursday's strong rally.

Benzinga • Jun 26, 2026